rf-fullcolor.png

 

September 11, 2013
by Louise Zornoza

India Releases Clinical Trial Adverse Event Compensation Formula

India's Central Drugs Standard Control Organization (CDSCO) has issued a "provisionally final" formula to be used in determining the amount of compensation that a clinical trial sponsor must pay a clinical trial subject for an adverse event or death related to the trial. 

According to the formula, the compensation amount for an adverse event or death would vary from a minimum of Rs.4 lacs (approximately $6,300 to a maximum of Rs.73.60 lacs (approximately $1,150,000) depending on the age of the trial subject and the risk factor-the seriousness and severity of the disease, presence of co-morbidity and duration of disease of the subject at the time of enrollment in the trial.

The formula was developed by three Independent Expert Committees convened by the CDSCO according to the provisions of the 1 January 2013, amendment to the Drugs and Cosmetics Rules to determine the amount of compensation, if any, to be paid by the sponsor or his representative.

When an adverse event occurs during a clinical trial, an Independent Expert Committee will evaluate it and make a recommendation to CDSCO within 30 days as to appropriate compensation. CDSCO will issue an order with a final decision within three months of receiving the Committee's recommendation, and the sponsor will then have 30 days to pay.

Editor's note: The exact compensation amounts have been corrected and now include the price in rupees.

CDSCO Formula

Read all Breaking News from RegLink

×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.